Stay updated with breaking news from Garyd Steinberg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy -
Investigators reported preserved or improved quality of life, especially with respect to pain. Patient-reported outcomes show that first-line enfortumab vedotin plus pembrolizumab for advanced UC improves quality of life.
Investigators describe oncologic outcomes in patients with progressive or de novo bladder cancer managed with and without neoadjuvant chemotherapy.
For those who are candidates, data are lacking on how to choose between available options
Investigators describe oncologic outcomes in patients with progressive or de novo bladder cancer managed with and without neoadjuvant chemotherapy.